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Abstract: The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed  
in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and 
development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is 
used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is 
dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled 
trastuzumab may be used to determine HER2 expression levels and guide therapy 
selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab 
preparation method that can be efficiently applied for clinical grade production. Also, 
relative HER2 expression levels in orthotopic and metastatic breast cancer models were 
assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method. 









The human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor 
receptor (EGFR) tyrosine kinase family [1]. Heterodimerization of HER2 with other members of the 
EGFR family promotes cell proliferation, survival, and migration. HER2 gene amplification and 
overexpression of HER2 protein is present in multiple malignancies including 20–30% of invasive 
breast cancers [2–5]. The association of HER2 with resistance to hormone therapy, chemotherapy, and 
conventional radiation therapy makes it an attractive target for breast cancer treatment [2,3,6]. 
Trastuzumab (HerceptinTM, Genentech, South San Francisco, CA, USA) is a monoclonal antibody 
that targets the extracellular domain of HER2 and is widely used for the treatment of HER2 positive 
breast cancer [7]. The standard of care for locally advanced HER2 positive breast cancer is combination 
treatment with trastuzumab, chemotherapy, and radiation therapy [8]. In addition to use as a first-line 
therapy, trastuzumab is used in the recurrent and metastatic settings [7]. An improvement in survival 
was seen in patients with HER2 positive metastatic disease receiving trastuzumab [9,10]. 
Although multiple studies have confirmed that trastuzumab is beneficial for the treatment of HER2 
positive breast cancer [3,7,9–11], the clinical efficacy is dependent on the level of HER2 expression [12]. 
Two FDA-approved techniques exist to evaluate HER2 expression level, including immunohistochemistry 
(IHC) and fluorescence in situ hybridization (FISH) [13]. Discrepancies have been observed between 
the two methods [14]. In addition, HER2 expression can vary over the course of therapy [15,16] and 
over the course of the disease [15]. HER2 expression has been demonstrated to be discordant between the 
primary lesion and distant metastatic lesions, and, moreover, may vary across metastatic lesions [17–20]. 
Thus, the use of repeated biopsies during the course of the disease may not be clinically feasible due to 
their invasiveness and not all lesions are readily accessible to be biopsied [21]. Therefore, a method 
that can reliably detect HER2 expression in individual lesions would be of critical importance in 
identifying patients who benefit from HER2-targeted therapy. Molecular imaging is a potentially less 
invasive solution for HER2 determination [22–26]. 
The development of radiolabeled antibodies and antibody fragments for cell-surface receptor 
detection is an active area of research [27]. Trastuzumab has been radiolabeled with 111In, 64Cu, and 89Zr, 
for in vivo SPECT and PET imaging of HER2 in xenograft models of ovarian and breast cancer [22–25]. 
89Zr is an ideal radionuclide for evaluation of intact antibodies because the extended half-life of  
89Zr (74.8 h) allows for imaging at 72–120 h when antibodies begin to equilibrate in the body [28]. 
Multiple studies have evaluated the use of 89Zr for studying antibody biodistribution [28–32]. 
Dijkers et al. studied the biodistribution of 89Zr-radiolabeled trastuzumab in 14 patients with HER2+ 
metastatic breast cancer [28] and demonstrated the feasibility of 89Zr-trastuzumab to detect HER2 
expression in vivo. They utilized a multi-step procedure with a succinylated derivative of the bifunctional 
chelator, desferrioxamine B (N-sucDf), for conjugation to trastuzumab and subsequent radiolabeling 
with 89Zr [33]. Recently, a simpler method of chelator-antibody conjugation chemistry was described 
with the p-isothiocyanatobenzyl derivative of desferrioxamine B (Df-Bz-NCS) [34,35]. This two-step 
production method may be readily applied to good manufacturing production of 89Zr-trastuzumab. The 
purpose of the current study was to evaluate the facile preparation method for 89Zr-trastuzumab 
production and the utility of 89Zr-trastuzumab, as prepared by this two-step production method, to 
characterize HER2 expression in orthotopic and metastatic breast cancer models. 




2. Experimental Section 
2.1. Flow Cytometry 
MDA435/LCC6HER2/GFP/Luc (HER2+) and MDA435/LCC6Vector (HER2−) cell lines, which overexpress 
and minimally express HER2/neu, respectively, were generous gifts from Dawn Waterhouse  
(BC Cancer Agency, Vancouver, BC, Canada). The HER2+ cell line constitutively expresses luciferase 
allowing for bioluminescent imaging in the presence of luciferin. Cells were grown in Dulbecco’s 
Modified Eagle Media supplemented with 10% fetal bovine serum until 80% confluent. Cells were 
harvested with Cell Dissociation Buffer (Invitrogen, Carlsbad, CA, USA), washed with PBS, and 
incubated on ice with 20 μg/mL trastuzumab. After 1 h, cells were washed with PBS and  
incubated with Alexa Fluor 546 goat anti-human IgG (Invitrogen) for 30 min. HER2 expression was  
analyzed (30,000 events collected) with the FACSAria Flow Cytometer (Becton Dickinson, Franklin 
Lakes, NJ, USA). 
2.2. 89Zr Production and Antibody Labeling 
89Zr-oxalate was produced via the 89Y(p,n)89Zr transmutation reaction on the CS-15 cyclotron 
(Cyclotron Corporation, Berkeley, CA, USA) as described previously [33,36]. The resulting 89Zr-oxalate 
was produced with a specific-activity of 8.1–15.4 GBq/μmol (220–418 mCi/μmol). Trastuzumab was 
incubated with Df-Bz-NCS (Macrocyclics, Dallas, TX, USA) in 0.1 M NaHCO3 buffer pH 9.0 at room 
temperature for 30 min in a 1:5 molar ratio. The resulting product, Df-Bz-NCS-trastuzumab, was 
purified via Zeba Spin Desalting Columns (Pierce Biotechnology, Rockford, IL, USA). 89Zr was 
complexed with Df-Bz-NCS-trastuzumab at a ratio of 0.22 MBq/μg (6 μCi/μg) of antibody in 0.5 M 
HEPES buffer pH 7.0 at 37 °C for 1 h with constant agitation on an orbital mixer. Approximately 100 µg 
of antibody was used per reaction. 89Zr-trastuzumab was purified with Zeba Spin Desalting Columns 
and radiochemical purity was determined by radio-TLC using a mobile phase of 50 mM DTPA and 
analytical size-exclusion chromatography (Superose 12 10/300 GL, GE Healthcare, Piscataway, NJ, 
USA) with 20 mM HEPES and 150 mM NaCl (pH 7.3) eluted at a flow rate of 0.75 mL/min. 
Millenium 32 software (Waters, Milford, MA, USA) was used to quantify chromatograms by integration. 
2.3. Immunoreactive Fraction 
The immunoreactive fraction of 89Zr-trastuzumab was determined using a cell-binding assay, as 
previously described by Lindmo et al. [37]. HER2+ cells were suspended in microfuge tubes at 
increasing concentrations ranging from 0.5 to 5 × 106 cells in 500 μL PBS. Approximately 37 kBq/0.25 μg 
of 89Zr-trastuzumab in 50 μL were added to each tube (n = 3) and agitated on an orbital mixer  
for 60 minutes at 25 °C. Cells were pelleted by centrifugation, washed twice with PBS, and subsequently 
counted for 89Zr activity. The specific binding was calculated as the ratio of bound radioactivity to the 
total amount of administered activity and was background corrected. To determine binding specificity, 
similar studies were performed with the addition of 100 μg of non-radiolabeled trastuzumab in HER2+ 
cells and also in HER2− cells. 
  




2.4. Animal Studies 
4 × 106 HER2+ or HER2− cells were injected into the mammary fat pad of athymic nude mice  
6–8 weeks of age. Tumors grew for 6 weeks until they reached approximately 10 mm in greatest 
dimension. A metastatic model was created by injection of 2 × 106 HER2+ cells into the tail vein of 
athymic nude mice as previously reported [38]. As the HER2+ cells constitutively express luciferase, 
bioluminescent imaging was performed 6 weeks after tail vein injection to evaluate the development of 
metastatic lesions. 
2.4.1. Biodistribution Studies 
In vivo biodistribution studies were performed to determine the uptake of 89Zr-trastuzumab in 
HER2+ and HER2− tumors in relation to normal organs. 0.55 MBq (15 μCi)/3.75 μg of 89Zr-trastuzumab 
was administered via intravenous tail vein injection. Mice were sacrificed at 24 and 96 h post-injection 
by cervical dislocation and tumor and select organs were harvested. Specific uptake for each tissue was 
measured with background and decay correction and expressed as % injected dose per gram of  
tissue (% ID/g) as calculated by normalization to the total activity injected. 
2.4.2. MicroPET/CT Studies 
MicroPET/CT experiments were performed with the Inveon MicroPET/CT scanner (Siemens, 
Knoxville, TN, USA). Mice were administered 89Zr-trastuzumab(3.0–3.7 MBq (80–100 μCi)/20–25 μg 
in 100 μL 0.9% sterile saline) via tail vein injection when orthotopic tumors reached 10–15 mm in greatest 
dimension or when bioluminescent areas were observed on the BLI scans for the metastatic model.  
At 24 and 96 h post-injection, mice were anesthetized with 2% isoflurane and imaged. Static images 
were collected for 20 min and co-registered with image display software (Inveon Research Workplace 
Workstation, Siemens, Schenectady, NY, USA). Regions of interest were drawn and the mean 
standard uptake values for tumors were determined using the formula: SUV = [(MBq/mL) × (animal 
wt. (g))/injected dose (MBq)]. 
2.5. Immunohistochemistry 
Tumors were harvested after completion of MicroPET/CT imaging studies and immediately fixed 
in 10% formalin. After allowing for the radioactivity to decay to background levels, tumors were 
embedded in paraffin. Five-micron sections were prepared and blocked in Dako Protein Block  
(Dako, Carpinteria, CA, USA) for 30 min at room temperature. Antigen retrieval was performed in 
citrate-based buffer using a pressure cooker (Biocare Medical). The sections were incubated with 
rabbit polyclonal anti-HER2 primary antibody (1:200, Abcam, Cambridge, MA, USA) overnight at 4 °C 
and visualized with Alexa Fluor 555-conjugated goat anti-rabbit IgG (1:200, Invitrogen). Sections 
were mounted were mounted with SlowFade Gold antifade reagent with 4,6-diamidino-2-phenylindole 
(DAPI) (Invitrogen) and cover slipped. Images were obtained with a Soft Imaging Solutions FVII cooled 
monochrome digital camera, Peltier cooled to −10 °C (Olympus America, Center Valley, PA, USA). 
  




2.6. Statistical Analysis 
The unpaired, two-tailed Student’s t-test was utilized for data analysis. Differences at the  
95% confidence level (P < 0.05) were considered to be statistically significant. 
3. Results and Discussion 
3.1. Trastuzumab Conjugation, Radiolabeling, and Stability Testing 
Trastuzumab was successfully conjugated to Df-Bz-NCS and radiolabeled with 89Zr. The radiolabeling 
efficiency was 78.4% ± 11.3%, the radiochemical purity was 98.7 ± 1.2%, and the specific activity  
was 136.9 ± 22.2 MBq/mg (3.7 ± 0.6 mCi/mg) (n = 9). 
3.2. Flow Cytometry and Binding Studies 
To evaluate the relative expression levels of the HER2 expression on each cell line, flow cytometry 
was performed. MDA435/LCC6HER2/GFP/Luc (HER2+) cells demonstrated elevated levels of HER2 
expression in comparison to MDA435/LCC6Vector (HER2−) cells which demonstrated minimal 
expression (Figure 1). 
Figure 1. Flow cytometric analysis of HER2/neu expression. The MDA-MB-435-HER2-luc 
and MDA-MB-435 breast cancer cell lines were evaluated for HER2/neu expression. 
Trastuzumab was used as the primary antibody, and FITC-conjugated goat anti-human IgG 
was used as the secondary antibody. Data are shown as cell number on the ordinate access 
and HER2/neu intensity on the abscissa. 
 
The immunoreactive fraction of 89Zr-trastuzumabwas 95.6% (Figure 2A). The uptake of  
89Zr-trastuzumab was 8.5-fold greater in the HER2+ cells compared to the HER2− cells (P < 0.01) 
(Figure 2B). Pre-incubation with excess unlabeled trastuzumab significantly inhibited the uptake of 
89Zr-trastuzumab in HER2+ cells (Figure 2B). 




Figure 2. Cell binding studies. (A) Plot of the (total/bound) activity versus (1/[normalized cell 
concentration]), used to calculate the immunoreactive fraction of 89Zr-Df-NCS-trastuzumab 
in MDA-MB-435-Her2-luc cells by extrapolation to the y-intercept; (B) Cell uptake curves 
of Fraction bound versus normalized cell concentration in MDA-MB-435-Her2-luc and  
MDA-MB-435-luc. A blocking dose of unlabeled trastuzumab inhibited the binding of 
89Zr-radiolabeled trastuzumab. 
 
3.3. Biodistribution Studies 
Biodistribution studies with 89Zr-trastuzumab were performed in athymic nude mice bearing 
HER2+ or HER2− tumors. Uptake of 89Zr-trastuzumab in HER2+ tumors was elevated after 24 h  
(26.9 ± 1.04% ID/g) and continued to remain elevated at 96 h post-injection (28.83 ± 1.33% ID/g) 
resulting in tumor to muscle ratios (T/M) of 8.7 ± 1.2 and 14.5 ± 2.9, respectively. In contrast,  
89Zr-trastuzumab uptake in HER2− tumors was significantly lower at 24 h (8.40 ± 0.72% ID/g)  
and 96 h (7.91 ± 0.96% ID/g) in comparison to HER2+ tumors (P < 0.001 at 24 and 96 h), resulting in 
T/M of 3.0 ± 0.4 and 3.4 ± 0.6, respectively. The circulating levels of 89Zr-trastuzumab in the blood 
declined from 23.6 ± 2.4% ID/g at 24 h to 14.3 ± 2.1% ID/g at 96 h (P < 0.001). Bone uptake increased 
from 4.8 ± 0.5%ID/g at 24 h to 10.0 ± 1.4% ID/g at 96 h. The uptake for each selected organ at 24 and 
96 h is shown in Figure 3A,B, respectively. 
A 
B 




Figure 3. Biodistribution of 89Zr-radiolabeled trastuzumab in MDA-MB-435-Her2-luc and 
MDA-MB-435-luc orthotopic xenograft models at (A) 24 h and (B) 96 h post-injection. 




3.4. Imaging Studies 
MicroPET/CT imaging studies demonstrated high uptake of 89Zr-trastuzumab in HER2+ tumors when 
compared to HER2− tumors at 24 h and 96 h (Figure 4A,B, respectively). The uptake in HER2− tumors 
was minimally increased compared to background. The SUVmean for 89Zr-trastuzumab for HER2+ and 
HER2− were 2.4 ± 0.3 and 1.4 ± 0.3 at 24 h (P = 0.003), and 3.1 ± 0.4 and 1.2 ± 0.1 at 96 h (P < 0.001), 
respectively. The level of 89Zr-trastuzumab in the blood significantly decreased from 24 to 96 h 
(A) 
(B) 




(SUVmean 1.7 ± 0.2 and 1.2 ± 0.3, respectively) as evidenced by visualization of the decreased radioactivity 
in the blood pool in the heart and the inferior vena cava. Uptake in the liver (SUVmean 0.82 ± 0.4) and 
kidney (SUVmean 0.58 ± 0.3) were low compared to HER2+ tumors at 96 h. 
Figure 4. Representative microPET/CT images obtained at 24 and 96 h in (A) and (B) 
respectively. Tumors implanted in the right mammary fat pad of each mouse. The axial (1), 
sagittal (2), and coronal (3) slices at the center of the tumor are demonstrated along with 
the maximal intensity projection reconstruction (4). The scale expressed as standardized 
uptake value (SUV) is demonstrated at the far right. 
 
For the metastatic tumor model, bioluminescent imaging demonstrated the development of metastasis 
in the jaw (SUVmean 2.6) and in the mid-thorax region (SUVmean 2.9). These lesions were readily 
visualized by microPET/CT demonstrating the potential use of 89Zr-trastuzumab for characterizing 
HER2 expression in metastatic lesions (Figure 5). 
A
B




Figure 5. Detection of Her2+ metastatic lesions. 2 × 106 MDA-MB-435-Her2-luc cells were 
administered via tail vein injection. Six weeks later, bioluminescent imaging (far right panel) 
demonstrated development of metastasis in the head and thoracic region. MicroPET/CT 
imaging using 89Zr-radiolabeled trastuzumab was able to localize these lesions to the L jaw 
and thoracic vetebral body. Shown are the axial (A), sagittal (B), and coronal (C) slices at 
the center of the tumor. 
 
3.5. Immunohistochemistry 
To confirm that HER2 expression levels in tumors related to HER2 expression in vitro, 
immunofluorescence staining was performed with an anti-HER2 antibody. Images were acquired 
under the same conditions and displayed on the same scale to ensure that the relative brightness 
observed in images reflected differences in HER2 expression level. A high level of HER2 staining 
(red) was seen in the HER2+ tumors when compared with the HER2− tumors. DAPI (blue) was used 
as the counterstain for the nucleus (Figure 6). 
3.6. Discussion 
In the current study, elevated 89Zr-trastuzumab uptake was associated with the HER2 overexpression 
in breast cancer cells in both orthotopic mammary fat pad and metastatic tumor models. HER2+ tumors 
were clearly distinguished from HER2− tumors by microPET/CT imaging with this agent. Elevated 
89Zr-trastuzumab uptake in HER2+ tumors in comparison to low normal tissue uptake resulted in high 
resolution images with excellent contrast between the tumor and normal tissues. The circulating blood 




levels of 89Zr-trastuzumab continued to decline over 4 days while the uptake in HER2+ tumors 
remained elevated. 
Figure 6. Immunofluorescent staining to evaluate the relative levels of HER2/neu 
expression for each tumor type. HER2/neu staining is demonstrated in red with a 
counterstain for the nucleus in blue. 
 
Previous studies utilized a multi-step procedure with a succinylated derivative of desferrioxamine B 
for conjugation to trastuzumab. Vosjan et al. have reported a simple, efficient method for the radiolabeling 
of antibodies with 89Zr [35]. However, this procedure has not been evaluated for 89Zr-radiolabeling of 
trastuzumab. In the current study, the 89Zr-radiolabeling of trastuzumab was completed in approximately 
3 h. The relative ease of the two-step procedure used in the current study makes it feasible for 
incorporation into good manufacturing practice grade production and for widespread clinical use. 
Both an orthotopic mammary fat pad and metastatic model was utilized in the current study.  
89Zr-trastuzumab produced with the simpler method was able to characterize HER2 expression in 
tumors from the orthopic and metastatic mouse models. While previous studies utilized heterotopic 
subcutaneous xenograft models for ovarian and breast cancer [24,39,40], the orthotopic model may be 
more clinically relevant by mimicking the tumor microenviroment and vasculature. Our results are in 
agreement with Dijkers et al., who reported an uptake value of ~33% ID/g in HER2/neu positive 
hindlimb tumors. In contrast, Holland et al. reported 2.5-fold higher uptake values (~73–86% ID/g) in 
subcutaneous shoulder tumors [39]. These differences may be explained by the different levels of 
HER2/neu expression in the varying cell lines used between the studies and also by differences in 
tumor perfusion due to the different locations of tumor growth. 
The metastatic breast cancer model utilized in the current study was developed via tail vein 
injection of HER2+ cells. The development of tumors was initially monitored via bioluminescent 
imaging. This model is more of a measure of tumor invasiveness rather than metastasis as distant sites 
are not derived from cells migrating from a primary tumor. Despite this caveat, this model was suitable 
for evaluating the ability of 89Zr-trastuzumab to detect HER2 expression in distant sites of disease. The 
3.3 day half-life of 89Zr is ideal for imaging full, intact antibodies (150 kDa) which require multiple 




days for equilibration as demonstrated in this study and previous studies [40]. Because 89Zr is 
relatively biologically inert, 89Zr-radiolabeled antibodies have low background uptake and improved 
stability in comparison to other radionuclides such as 64Cu, which is readily transchelated by liver 
superoxide dismutase resulting in elevated liver uptake, or some 124I-radiolabeled compounds which 
are may be dehalogenated and taken up by the thyroid. There is some residual bone uptake of  
89Zr (5–10%) which may be attributed to a slow rate of intratumoral metabolism of 89Zr-trastuzumab 
leading to transmetalation of 89Zr4+ ions which are sequestered in the bone [39]. Further studies on the 
metabolism of 89Zr-trastuzumab are underway by our group and others. 
89Zr-trastuzumab has significant clinical potential for the detection and characterization of lesions 
for HER2 status. Confirmation of HER2 status is necessary prior to initiation of trastuzumab therapy. 
Immunohistochemical staining and fluorescence-in-situ hybridization techniques from biopsy specimens 
taken at initial diagnosis are the current standards for determining HER2 expression [13]. However, 
tumor heterogeneity plays a significant role in breast cancer [41] and HER2 expression and gene 
amplification may vary across the primary tumor. Moreover, differences in the extent of HER2 
expression between the primary tumor and across metastatic lesions have been reported [17,42]. As 
demonstrated in this study, PET imaging with 89Zr-trastuzumab provides a comprehensive view of the 
HER2 status not only within the primary tumor, but also across metastatic lesions. PET imaging with 
89Zr-trastuzumab may assist in the stratification of patients by HER2 status for decision-making about 
trastuzumab therapy. With the increased costs of healthcare, a method to select patients that benefit 
from trastuzumab therapy, while avoiding the unnecessary treatment of patients with low HER2 
expressing tumors could have an impact on cancer treatment. 
Although beyond the scope of this study, PET with 89Zr-trastuzumab may improve the ability to 
detect lesions not previously detected on routine staging studies such as CT, MRI, or bone scan. In a 
feasibility study involving 14 patients with metastatic breast cancer, 89Zr-trastuzumab PET imaging 
provided complementary information to CT, MRI, and bone scan [28]. Of note, 89Zr-trastuzumab PET 
imaging was able to reveal previously undetected brain metastases [28]. Determination of the 
sensitivity and specificity of 89Zr-trastuzumab PET imaging and correlation with HER2 status in 
pathological human specimens will be challenging as it is unethical to subject patients to the 
discomfort of additional unnecessary biopsies. 
Quantitative pre-therapy imaging studies with 89Zr-radiolabeled trastuzumab may also provide 
individualized pharmacokinetic and biodistribution information necessary to determine the optimal 
dose of trastuzumab for each patient. Scouting studies with 89Zr-radiolabeled trastuzumab may provide 
information regarding tumor uptake in comparison to critical normal organs allowing for maximal 
tumor targeting while minimizing normal tissue toxicity. Thus, 89Zr-trastuzumab imaging can provide 
this information in an efficient and safe manner, with fewer patients treated at a suboptimal dose. 
4. Conclusions 
The p-isothiocyanatobenzyl derivative of desferrioxamine B was utilized for radiolabeling of 
trastuzumab. Although beyond the scope of this study, this two-step procedure may be easily applied 
to preparation of 89Zr-radiolabeled trastuzumab for clinical use. Biodistribution and imaging studies 
demonstrated comparable results to those previously reported with the succinylated deravitave of 




desferrioxamine used in preparation of 89Zr-trastuzumab. 89Zr-trastuzumab PET imaging is a non-invasive 
method for characterizing HER2 expression in primary and distant lesions. This information may be 
useful in selecting patients that benefit most from trastuzumab therapy. 
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